$NRIX
Nurix Therapeutics, Inc.

2022 Q2 Form 10-Q Financial Statement

#000156459022025450 Filed on July 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $11.43M $9.621M $7.396M
YoY Change 61.22% 92.0% 10.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.654M $9.228M $8.818M
YoY Change 28.53% 41.32% 41.09%
% of Gross Profit
Research & Development $47.49M $43.14M $36.53M
YoY Change 82.71% 87.53% 78.64%
% of Gross Profit
Depreciation & Amortization $1.282M $991.0K $757.0K
YoY Change 97.84% 54.84% 18.28%
% of Gross Profit
Operating Expenses $57.15M $52.37M $45.35M
YoY Change 70.56% 77.31% 69.85%
Operating Profit -$45.72M -$42.74M
YoY Change 73.07% 74.31%
Interest Expense $314.0K $211.0K $295.0K
YoY Change 83.63% -34.06% 110.71%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$45.40M -$42.53M -$37.66M
YoY Change 73.0% 75.73% 89.52%
Income Tax $0.00 $0.00 $44.00K
% Of Pretax Income
Net Earnings -$45.40M -$42.53M -$37.70M
YoY Change 72.09% 75.21% 89.32%
Net Earnings / Revenue -397.14% -442.09% -509.76%
Basic Earnings Per Share -$1.01 -$0.95
Diluted Earnings Per Share -$1.01 -$951.7K -$846.3K
COMMON SHARES
Basic Shares Outstanding 44.90M 44.74M
Diluted Shares Outstanding 44.90M 44.69M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $296.4M $261.1M $295.4M
YoY Change -23.22% -13.86% 5.14%
Cash & Equivalents $41.53M $78.78M $80.51M
Short-Term Investments $255.7M $183.2M $215.2M
Other Short-Term Assets $10.41M $11.20M $9.480M
YoY Change 127.26% 202.78% 55.41%
Inventory
Prepaid Expenses
Receivables $0.00 $8.000M $6.000M
Other Receivables $0.00 $204.0K $204.0K
Total Short-Term Assets $306.8M $280.5M $311.1M
YoY Change -22.58% -9.74% 4.25%
LONG-TERM ASSETS
Property, Plant & Equipment $15.51M $13.52M $11.34M
YoY Change 85.82% 94.28% 69.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $51.54M $123.7M $137.2M
YoY Change -53.33% 60.21% 50.92%
Other Assets $5.058M $4.157M $2.833M
YoY Change 73.52% 164.61% 1500.56%
Total Long-Term Assets $87.52M $157.2M $165.7M
YoY Change -28.08% 83.06% 69.19%
TOTAL ASSETS
Total Short-Term Assets $306.8M $280.5M $311.1M
Total Long-Term Assets $87.52M $157.2M $165.7M
Total Assets $394.3M $437.7M $476.8M
YoY Change -23.88% 10.35% 20.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.142M $6.014M $6.650M
YoY Change 13.64% 37.06% 94.9%
Accrued Expenses $25.20M $16.85M $18.40M
YoY Change 228.26% 56.01% 121.64%
Deferred Revenue $43.19M $41.21M
YoY Change 31.86% 25.65%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.67M $66.05M $66.26M
YoY Change 55.12% 37.68% 48.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $54.91M $65.75M $68.21M
YoY Change -24.74% 7803.13% 7924.82%
Total Long-Term Liabilities $54.91M $65.75M $68.21M
YoY Change -24.74% 7803.13% 7924.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.67M $66.05M $66.26M
Total Long-Term Liabilities $54.91M $65.75M $68.21M
Total Liabilities $127.6M $131.8M $134.5M
YoY Change 6.48% 4.17% 26.77%
SHAREHOLDERS EQUITY
Retained Earnings -$308.8M -$263.4M -$220.9M
YoY Change 105.82% 113.01%
Common Stock $563.8M
YoY Change 43.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $266.7M $305.9M $342.3M
YoY Change
Total Liabilities & Shareholders Equity $394.3M $437.7M $476.8M
YoY Change -23.88% 10.35% 20.29%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$45.40M -$42.53M -$37.70M
YoY Change 72.09% 75.21% 89.32%
Depreciation, Depletion And Amortization $1.282M $991.0K $757.0K
YoY Change 97.84% 54.84% 18.28%
Cash From Operating Activities -$32.91M -$42.60M -$30.91M
YoY Change 4.38% -629.0% 50.93%
INVESTING ACTIVITIES
Capital Expenditures -$2.789M $3.472M -$862.0K
YoY Change 33.19% 311.86% -4.22%
Acquisitions
YoY Change
Other Investing Activities -$1.976M $43.50M -$35.66M
YoY Change -96.41% -2924.87% -71.16%
Cash From Investing Activities -$4.765M $40.03M -$36.52M
YoY Change -91.66% -1777.04% -70.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 432.0K 1.488M 500.0K
YoY Change -99.71% 9.49% -144.25%
NET CHANGE
Cash From Operating Activities -32.91M -42.60M -30.91M
Cash From Investing Activities -4.765M 40.03M -36.52M
Cash From Financing Activities 432.0K 1.488M 500.0K
Net Change In Cash -37.25M -1.111M -66.93M
YoY Change -160.24% -115.81% -54.21%
FREE CASH FLOW
Cash From Operating Activities -$32.91M -$42.60M -$30.91M
Capital Expenditures -$2.789M $3.472M -$862.0K
Free Cash Flow -$30.12M -$46.07M -$30.05M
YoY Change 2.33% -739.0% 53.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44898409
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43804066
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44797235
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41318281
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
255746000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1064000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6071000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1458000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
305917000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
424000
CY2022Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
47000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-42533000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
432000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-45401000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
266739000
us-gaap Profit Loss
ProfitLoss
-87934000
us-gaap Profit Loss
ProfitLoss
-50657000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2273000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1288000
us-gaap Share Based Compensation
ShareBasedCompensation
12846000
us-gaap Share Based Compensation
ShareBasedCompensation
6644000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-993000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-566000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2612000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1576000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-201000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2537000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-704000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1515000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
837000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1747000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2119000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13052000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
19899000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2548000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1555000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2824000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-692000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75544000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23482000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
80031000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
183238000
nrix Proceeds From Sales Of Investments
ProceedsFromSalesOfInvestments
6994000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
121558000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
119681000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6261000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2934000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35266000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59497000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150157000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
856000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
631000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1064000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
188377000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1043000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
170000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42434000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
188377000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308800000
CY2022Q2 nrix Cash Cash Equivalents And Investments
CashCashEquivalentsAndInvestments
348800000
nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1920000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151830000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38358000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
68851000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42434000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2693000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
607000
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
82000
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
144000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41533000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188207000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
901000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and investments. The Company’s investments consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or investments.</p>
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13343000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3342000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10903000
CY2020Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
8276000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1576000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1555000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-692000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
32200000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26219000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16693000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14879000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15507000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2300000
CY2022Q1 nrix Lessee Operating Lease Liability To Be Paid Year One Per Month
LesseeOperatingLeaseLiabilityToBePaidYearOnePerMonth
153813
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2021Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
14549000
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
CY2022Q1 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
46434
CY2022Q2 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2022Q2 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2022Q1 nrix Lease Commencement Date
LeaseCommencementDate
2022-08-01
CY2022Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2035-03-01
CY2022Q1 nrix Operating Lease Rent Payable Per Month
OperatingLeaseRentPayablePerMonth
205084
CY2022Q1 nrix Percentage Of Increase Of Annual Rent
PercentageOfIncreaseOfAnnualRent
0.03
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7856000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8854000
CY2022Q2 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
7765000
CY2021Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
4158000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1847000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2022Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
26000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
75000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2240000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
659000
CY2022Q2 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
19734000
CY2021Q2 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2021Q2 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
CY2022Q2 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
CY2021Q2 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-04-30
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320
CY2021Q3 nrix Lease Commencement Date
LeaseCommencementDate
2021-12-01
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2022Q2 nrix Lessee Operating Lease Liability Undiscounted Lease Payments Related To Lease
LesseeOperatingLeaseLiabilityUndiscountedLeasePaymentsRelatedToLease
34314000
us-gaap Operating Lease Payments
OperatingLeasePayments
3564000
us-gaap Operating Lease Payments
OperatingLeasePayments
1792000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4804000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2097000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2753000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6976000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7422000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4330000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2670000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2750000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
22556000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
49457000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
630000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14513000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5470000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9043000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14513000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11333826
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9476306
CY2022Q2 nrix Share Based Compensation Arrangement By Share Based Payment Award Options Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesSubjectToRepurchase
33300
CY2022Q2 nrix Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Value Of Shares Subject To Repurchase
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseValueOfSharesSubjectToRepurchase
200000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
68200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2021Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-45401000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26382000
us-gaap Net Income Loss
NetIncomeLoss
-87934000
us-gaap Net Income Loss
NetIncomeLoss
-50657000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44898409
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43804066
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44797235
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41318281
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7227702
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5276651

Files In Submission

Name View Source Status
0001564590-22-025450-index-headers.html Edgar Link pending
0001564590-22-025450-index.html Edgar Link pending
0001564590-22-025450.txt Edgar Link pending
0001564590-22-025450-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-10q_20220531.htm Edgar Link pending
nrix-10q_20220531_htm.xml Edgar Link completed
nrix-20220531.xsd Edgar Link pending
nrix-20220531_cal.xml Edgar Link unprocessable
nrix-20220531_def.xml Edgar Link unprocessable
nrix-20220531_lab.xml Edgar Link unprocessable
nrix-20220531_pre.xml Edgar Link unprocessable
nrix-ex311_6.htm Edgar Link pending
nrix-ex312_8.htm Edgar Link pending
nrix-ex321_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending